α1 Adrenergic blockers (prazosin/Minipress, terazosin/Hytrin, and doxazosin/Cardura) are approved antihypertensive drugs with a generally favorable profile of safety and tolerability. They have not gained widespread sustained use in hypertension because of their relatively limited monotherapeutic efficacy and their tendency to cause significant first-dose hypotension and sustained postural hypotension, both of which are magnified by salt depletion and interactions with diuretics and other antihypertensive medications. Opportunities remain for use in essential hypertension, especially with concomitant hypercholesterolemia or symptoms of prostatism. Other possible areas of use include Raynaud syndrome and cardiac failure, especially in combination with other agents.
KeywordsPharmacodynamic Interaction Adrenergic Blocker Orthostatic Tolerance Orthostatic Symptom Alpha Adrenergic Blocker
Unable to display preview. Download preview PDF.
- 1.Izzo JL Jr (1999) The sympathetic nervous system in human hypertension. In Izzo JL, Black HR, eds. Hypertension Primer, Lippincott Williams and Wilkins, pp. 109–112.Google Scholar
- 2.Berecek KH, Carey RM (1999) Adrenergic and dopaminergic receptors and actions. In Izzo JL, Black HR, eds. Hypertension Primer, Baltimore: Lippincott Williams and Wilkins, pp. 3–6.Google Scholar
- 3.Grimm RH (1999) Alpha adrenergic blockers. In Izzo JL, Black HR, eds. Hypertension Primer, Baltimore: Lippincott Williams and Wilkins, pp. 366–367.Google Scholar